Literature DB >> 7862875

Differential involvement of voltage-dependent calcium channels in apomorphine-induced hypermotility and stereotypy.

L Antkiewicz-Michaluk1, J Michaluk, I Romańska, J Vetulani.   

Abstract

The involvement of the voltage-dependent calcium channel in behavioral effects of apomorphine was tested in naive rats and in animals which were morphine-abstinent or were subjected to chronic electroconvulsive treatment (ECS). In naive rats a calcium channel blocker, nifedipine, which by itself does not affect locomotor activity, inhibited the locomotor stimulation induced by apomorphine, while it facilitated stereotyped behavior. Morphine-abstinent and ECS-treated rats displayed elevated responsiveness to apomorphine, reflected by hypermotility and stereotyped behavior after a dose of 1 mg/kg IP that does not produce overt behavioral effects in naive animals. Nifedipine, 5 mg/kg IP, significantly reduced hypermotility produced by apomorphine in morphine abstinent or ECS-treated rats. The calcium channel blocker did not, however, antagonize enhanced stereotyped behavior. The results indicate that apomorphine hypermotility is controlled by dihydropyridine calcium channels and that enhancement of calcium channel density produced by morphine abstinence and by chronic ECS potentiates the hypermotility response. Calcium channels seem to be differently involved in control of apomorphine-induced hypermotility and stereotypy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7862875     DOI: 10.1007/bf02245239

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  42 in total

Review 1.  Multiple calcium channels and neuronal function.

Authors:  R J Miller
Journal:  Science       Date:  1987-01-02       Impact factor: 47.728

2.  Cortical dihydropyridine binding sites and a behavioral syndrome in morphine-abstinent rats.

Authors:  L Antkiewicz-Michaluk; J Michaluk; I Romańska; J Vetulani
Journal:  Eur J Pharmacol       Date:  1990-05-03       Impact factor: 4.432

3.  Effect of apomorphine on motility in rats.

Authors:  J Maj; M Grabowska; L Gajda
Journal:  Eur J Pharmacol       Date:  1972-02       Impact factor: 4.432

4.  Yawning induced by apomorphine, physostigmine or pilocarpine is potentiated by dihydropyridine calcium channel blockers.

Authors:  A Bourson; P C Moser
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

5.  Calcium channel inhibitors prevent apomorphine- and oxytocin-induced penile erection and yawning in male rats.

Authors:  A Argiolas; M R Melis; G L Gessa
Journal:  Eur J Pharmacol       Date:  1989-08-03       Impact factor: 4.432

6.  Regional blockade by neuroleptic drugs of in vivo 3H-spiperone binding in the rat brain. Relation to blockade of apomorphine induced hyperactivity and stereotypies.

Authors:  C Köhler; L Haglund; S O Ogren; T Angeby
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

7.  Effects of intranigral injections of dopamine agonists and antagonists, glycine, muscimol and N-methyl-D,L-aspartate on locomotor activity.

Authors:  E A Jackson; P H Kelly
Journal:  Brain Res Bull       Date:  1984-08       Impact factor: 4.077

8.  Diltiazem suppresses apomorphine-induced fighting and pro-aggressive effect of withdrawal from chronic ethanol or haloperidol in rats.

Authors:  O Pucilowski; W Kostowski
Journal:  Neurosci Lett       Date:  1988-10-31       Impact factor: 3.046

9.  Prolonged morphine treatment increases rat brain dihydropyridine binding sites: possible involvement in development of morphine dependence.

Authors:  V Ramkumar; E E el-Fakahany
Journal:  Eur J Pharmacol       Date:  1988-01-27       Impact factor: 4.432

10.  Studies on possible mechanisms of action of electroconvulsive therapy; effects of repeated electrically induced seizures on rat brain receptors for monoamines and other neurotransmitters.

Authors:  J F Deakin; F Owen; A J Cross; M J Dashwood
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.